In this article, we show how expensive innovative treatments are sometimes only approved for reimbursement for narrow patient populations. This has adverse effects on all stakeholders, particularly those patients who miss out on potential health gains and quality of life improvements, and in some cases, on the chance to survive.
We outline how real-world evidence, value-based healthcare, innovative pricing models, and partnerships can help increase patient access to expensive innovative treatments.
Read the article here
For further information, please contact Managing Economist Tuomas Haanperä